Gemphire Therapeutics (GEMP) Reports Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients
Tweet Send to a Friend
Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line data based upon the Company’s preliminary review of the limited top-line data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
